GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) fell 4.2% on Thursday . The company traded as low as $20.65 and last traded at $20.65. 958,726 shares traded hands during mid-day trading, an increase of 1,875% from the average session volume of 48,553 shares. The stock had previously closed at $21.55.
GENMAB A/S/S Price Performance
The business’s 50-day moving average price is $22.19 and its two-hundred day moving average price is $25.17.
GENMAB A/S/S Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Recommended Stories
- Five stocks we like better than GENMAB A/S/S
- What is a Low P/E Ratio and What Does it Tell Investors?
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Texas Instruments: The Old-School Tech Titan Still Delivering
- Want to Profit on the Downtrend? Downtrends, Explained.
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
